The management of uterine bleeding in female transplant patients over a 3-year period at our institution was reviewed. A total of 33 females who had undergone allogeneic hematopoietic stem cell transplant were identified as having received gynecologic consultation for the diagnosis of menorrhagia. Hormone therapy achieved a resolution of symptoms in 32 (97%) of the patients, and 26 (79%) required only one hormone regimen. Following resolution of symptoms, transition to standard-dose oral contraceptive pills as maintenance therapy prevented recurrent menorrhagia due to high circulating estrogen levels. Alternatives for patients who are unable to tolerate oral administration and those with hepatotoxicity are also discussed.
Over the past 10 years, allogeneic bone marrow (BMT) and peripheral blood stem cell transplants (PBSCT) have become a more frequent part of disease management for both hematologic and solid tumor malignancies. Menorrhagia, or abnormal menstrual bleeding, is a gynecologic complication in female patients during the peri-transplant period. Often, menorrhagia occurs in the setting of thrombocytopenia, which may be associated with the disease. Treatment of the disease with chemo-and/or radiotherapy produces myelosuppression and less frequently platelet consumption, coagulopathies and medication-induced thrombocytopenia. 1, 2 Surgical management, such as dilation and curettage, endometrial ablation, uterine artery embolization, balloon cryotherapy and hysterectomy are frequently associated with a high level of morbidity in such patients, [3] [4] [5] [6] and thus are only employed when other methods of management have failed.
Options for medical management of menorrhagia in this patient population include the use of estrogen with or without a progesterone, and gonadotropin-releasing hormone (GnRH) agonists such as leuprolide. Leuprolide, administered as an intramuscular injection once every 1 or 3 months, has been shown to be effective in preventing menstrual bleeding in premenopausal women scheduled to undergo transplantation with BMT or PBSCT. 7 These studies documented effectiveness in 73% of BMT patients 8 and 96.5% of PBSCT patients. 9 In neither of these studies was the efficacy of this agent assessed in the treatment of menorrhagia during the peri-transplant period. Rather, the recommended use of leuprolide in this patient population is for protracted menstrual suppression when administered 1-2 months prior to transplant. Utilizing this agent early allows adequate time for menstrual bleeding to occur during the first month after administration, and prior to the chemo-/radiotherapy-induced marrow suppression. Unfortunately, many patients who are candidates for transplant do not have the luxury of the required 1-2 months lead time without marrow-suppressive therapy. We report our experience using a combination of estrogen/progestin therapy for the treatment of menorrhagia that can occur in patients during the peri-transplant time.
Patients and methods
The medical records of 337 patients who underwent hematopoietic stem-cell transplants during 1997-2001 on the adult and pediatric transplant services at the Memorial Sloan-Kettering Cancer Center (MSKCC) were reviewed. In all, 33 premenopausal female patients were identified via progress notes, discharge summaries, consultation records, pharmacy dispensaries and international classification of disease codes, as having been treated for menorrhagia by the inpatient gynecology consultation service during their admission for transplant, and after their stem cell infusion. Information on the reason for consultation, hormone and other gynecologic treatment, and outcome was abstracted from the medical record.
According to the supportive care practice guidelines of the MSKCC transplantation service, all premenopausal female patients received oral contraceptive pills (OCPs) containing ethinyl estradiol with a progestational agent, or medroxyprogesterone alone, unless they were already using another OCP. In the later group, patients were continued on their current preparation. In addition, platelet transfusions were administered routinely for a count of o20 Â 10 9 /l while patients were receiving their conditioning therapy, and during the early post-transplant nadir period. Generally, if active bleeding developed, the threshold for platelet transfusion was increased to o50 Â 10 9 /l.
Results
The median age of this group of women at the date of gynecologic consultation was 36 years (range 14-51). The majority of patients were undergoing transplantation for diagnoses of leukemia (67%), lymphoma (18%), solid tumors (9%) and myelodysplasia or aplastic anemia (3% each).
Gynecologic consultation occurred at a median of 12 days after transplantation (range 0-56). Of the evaluable patients, three (9%) had a history of more than one malignancy. In all, 31 (94%) patients were treated with both radiation and chemotherapy, whereas two (6%) patients received chemotherapy alone as their conditioning regimen. All evaluable patients had received cytarabine or cyclophosphamide in the chemotherapy portion of their conditioning regimens. The ranges for routine laboratory studies that could impact on coagulation, obtained on the date of consultation, are reported in Table 1 . Prior to consultation, 21 (64%) patients had been taking OCPs. In total, 27% (n ¼ 9) had received standard dose, while 12 (38%) were on high-dose OCPs (X50 mg of ethinyl estradiol with progesterone). One (3%) patient received medroxyprogesterone with conjugated estrogens and two patients (6%) received medroxyprogesterone alone. The remaining nine (30%) had not received any hormone manipulation by the transplant team prior to the consultation. Documentation explaining the rationale was not available in the medical records.
In all, 97% (n ¼ 32) of patients achieved a resolution of menorrhagia and 75% (n ¼ 25) required only one regimen of hormones to alleviate symptoms (see Table 2 ). In total, 19 were given single-drug therapy consisting of: high-dose OCPs (n ¼ 11), standard-dose OCPs (n ¼ 4), medroxyprogesterone (n ¼ 3) or transdermal (TD) estrogen (n ¼ 1). Five received medroxyprogesterone with either TD estrogen (n ¼ 3), high-dose OCPs (n ¼ 1) or oral conjugated estrogens (n ¼ 1). The remaining patient was given high-dose OCPs with TD estrogen (n ¼ 1).
Seven patients, who had cessation of menorrhagia, required more than one hormone regimen, and all were eventually changed to an OCP (see Table 3 ). Three patients, who initially experienced severe menorrhagia, received intravenous conjugated estrogens dosed at 25 mg every 6 h for 24 h as first-line therapy after consultation. After this initial treatment, all the three were successfully converted to high-dose OCPs. However, two patients who could not tolerate oral medications required TD estrogen prior to eventually changing OCPs due to their inability to tolerate oral medications as a result of their cancer treatment. Of the remaining four patients, three could not initially tolerate oral medications and thus were treated with TD estrogens. They were eventually changed to either high-dose OCPs (n ¼ 2) or standard-dose OCPs (n ¼ 1). The fourth patient initially received high-dose OCPs, but was changed to transdermal estrogens with medroxyprogesterone for unknown reasons. She was eventually given high-dose OCPs.
The patient, who did not achieve cessation of menorrhagia, had been on standard-dose OCPs prior to transplantation. After experiencing post-transplant menorrhagia, she was escalated to high-dose OCPs. The bleeding persisted and she was given a course of intravenous Table 1 Baseline laboratory values at the time of inpatient gynecologic consultation 
Discussion
Standard hematopoietic stem cell transplants, which employ high-dose chemo-and/or radiotherapy, induce bone marrow ablation and mucosal injury. These conditions may result in an increased risk of infection, bleeding, as well as the need for transfusion support. The risk of relapse in patients awaiting transplant frequently necessitates rapid transition from marrow suppressive antitumor therapy to hospitalization for the myeloablative transplant. As a consequence, premenopausal female patients may have very prolonged courses of menstrual suppression, during which hypertrophy of the uterine lining may occur. If these patients do not have the opportunity to experience withdrawal bleeding prior to beginning the stem cell transplant, menstrual bleeding during the therapy-induced pancytopenia can be problematic. Traditional therapy with high-dose OCPs can be a very effective treatment for menorrhagia in patients with chronic disease. In our retrospective analysis of transplant patients with menorrhagia, 18 (55%) patients received regimens with OCPs as a first-line treatment. All but one patient in this subset had resolution of their symptoms. Invasive measures, such as dilation and curettage, endometrial ablation, uterine artery embolization, balloon cryotherapy and hysterectomy, were not required in the peri-transplant period for any patients included in this analysis. This is important in a population of transplant patients who are high-risk surgical candidates. Nevertheless, if life-threatening hemorrhage occurs, and all other treatments have been exhausted, surgical intervention should be considered.
In patients who are unable to tolerate oral preparations due to severe mucositis, nausea or emesis, or in patients who experience elevations in bilirubin levels due to hemolysis or drug/treatment toxicity, TD and/or intravenous (IV) regimens proved to be as efficacious as OCPs. Furthermore, such agents avoid the risk of hematomas or infections that may be associated with an intramuscular injection of leuprolide to a pancytopenic patient.
Theoretically, the absorption of TD hormonal agents may vary with certain dermatologic conditions or as a result of dermatologic changes following total-body irradiation or associated with graft-versus-host disease. This, however, has not been studied formally in this patient population, and these agents were found in this analysis to be as effective as the oral or IV forms.
Other options that may be considered for recurrent, refractory or severe menorrhagia after an IV course of conjugated estrogens are high-dose OCPs given twice daily for up to 5 days or until bleeding stops. High-dose OCPs can then be dose-reduced to a single daily dose for the remainder of the 21-day pack, or continued until the platelet count and hemoglobin have recovered adequately and a withdrawal bleed is deemed to be safe. Alternatively, transitioning to continuous standard-dose regimens may also be effective.
High doses of ethinyl estradiol can also lead to menorrhagia from hypertrophy of the uterine lining. As discussed previously, whenever possible, patients who are on continuous OCPs should have a withdrawal bleed induced at least 1 month prior to transplant by discontinuing hormone therapy. This will help to prevent menorrhagia during the post-transplant period. If more than 1 month lead time is available prior to a transplant, the administration of a GnRH analog such as leuprolide is an ideal agent to induce amenorrhea and potentially prevent menorrhagia from occurring in the post-transplant period.
Finally, in patients who are treated for menorrhagia by a dose escalation from standard-dose OCPs to high-dose OCPs, it is recommended that standard-dose OCPs be reinstated as soon as hematologic indices normalize. This should prevent further menorrhagia, from endometrial hypertrophy, that may occur from long-standing high-dose OCP use. In addition, for hormone-naı¨ve patients, standard-dose OCPs may be a regimen to consider as first-line treatment for menorrhagia, reserving high-dose OCPs or intravenous conjugated estrogens for second-line agents. However, at this time, a prospective randomized controlled clinical trial is needed to best compare these treatments.
In hematopoietic stem-cell transplant patients who experience menorrhagia during treatment or in the posttransplant recovery phase, we recommend high-dose OCPs as first-line treatment for women already taking prophylactic regular-dose OCPs. For patients with abnormal liver function tests and/or contraindications to oral regimens, transdermal estrogen therapy with or without medroxyprogesterone proved equally effective and can be substituted until OCPs can be administered safely. In patients with recurrent, refractory or severe menorrhagia, intravenous conjugated estrogens may be used for a 24-h period, followed by high-dose or standarddose OCPs.
After resolution of symptoms, maintenance treatment with standard-dose OCPs is preferable, as prolonged administration of high-dose OCPs can lead to menorrhagia. Randomized, controlled, clinical trials are needed to further evaluate the most efficacious hormone regimen for the treatment of transplant-related menorrhagia. While its management is a significant clinical dilemma, the goal of treatment should be to prevent this complication, rather than be faced with its management at a critical time in the transplant course. Therapies directed at inducing amenorrhea need to be further evaluated, and whenever possible such treatment should be initiated well before transplantation is scheduled.
